Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
bevacizumab (avastin) (1 trial)
carboplatin (paraplatin) (1 trial)
paclitaxel (taxol) (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Lung Neoplasms (Phase 2)
Trials (1 total)
Trial APIs (3 total)